1 High-Yield Dividend Stock You Can Count on in 2023

NASDAQ: GILD | Gilead Sciences Inc. News, Ratings, and Charts

GILD – With the Federal Reserve committed to bringing inflation down, a pause in interest rate hikes is not expected this year. This is expected to lead to an economic slowdown and keep the stock market volatile. Amid this backdrop, investors could add a high-yield stock, Gilead Sciences (GILD), to stabilize their portfolio returns. Keep reading….

The stock market and the economy endured a challenging 2022 with several challenges, such as high inflation, rising interest rates, supply chain disruptions, and geopolitical issues.

Although inflation is showing signs of easing, the Federal Reserve remains committed to bringing inflation down to its desired 2% target. Therefore, a pause in rate hikes is highly unlikely this year.

This is expected to keep the economy and the stock market under pressure. Therefore, it could be wise to cushion one’s portfolios by adding high-yield dividend stock Gilead Sciences, Inc. (GILD - Get Rating).

Healthcare major GILD has been a solid dividend payer. It has raised dividends for seven consecutive years. The company paid a quarterly dividend of $0.73 on December 29, 2022. Its annual dividend of $2.92 yields 3.51% on the current share price. It has a four-year average yield of 4%. Its dividend payouts have increased at a 5% CAGR over the past three years and a 7% CAGR over the past five years.

GILD gained popularity during the pandemic by developing the first antiviral drug approved to treat COVID-19. GILD’s revenue and EPS in the fiscal third quarter of 2022 were higher than analyst estimates. Its EPS was 32.9% higher than the consensus estimate, while its revenue beat analyst estimates by 14.8%.

GILD’s Chairman and CEO, Daniel O’Day, said, “This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy in treatment, and we received our first approval for our long-acting HIV agent, lenacapavir, in Europe.”

The company raised its guidance for fiscal 2022. It now expects total product sales between $25.90 billion and $26.20 billion, up from the previously expected range of $24.50 billion to $25 billion. Its non-GAAP EPS is expected to come between $6.95 and $7.15, up from the $6.35 to $6.75 range expected earlier.

Here’s what could influence GILD’s performance in the upcoming months:

Strategic Agreement

On January 3, 2023, GILD and EVOQ Therapeutics, Inc. announced a collaboration and licensing agreement. Under the agreement, GILD would receive the rights to exclusively license EVOQ’s NanoDisc technology to develop and commercialize EVOQ’s proprietary technology for treating rheumatoid arthritis and lupus.

Robust Financials

GILD’s HIV product sales increased 7% year-over-year to $4.49 billion for the third quarter ended September 30, 2022. Its total product sales, excluding Veklury, increased 11% year-over-year to $6.05 billion. Also, its oncology sales rose 79% from the prior-year period to $578 million.

Discounted Valuation

GILD’s forward non-GAAP P/E of 11.71x is 42.7% lower than the 20.44x industry average. Its forward EV/EBITDA of 8.84x is 35.8% lower than the 13.77x industry average. Also, the stock’s 3.93x forward P/S is 16.9% lower than the 4.74x industry average.

High Profitability

In terms of the trailing-12-month gross profit margin, GILD’s 79.22% is 43.3% higher than the 55.29% industry average. Likewise, its 47.08% trailing-12-month EBITDA margin is significantly higher than the industry average of 3.73%. Furthermore, the stock’s 0.42% trailing-12-month asset turnover ratio is 22.9% higher than the industry average of 0.34%.

POWR Ratings Show Promise

GILD has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. GILD has an A grade for Value, in sync with its discounted valuation.

It has a B grade for Quality, consistent with its high profitability.

GILD is ranked #4 out of 399 stocks in the Biotech industry. Click here to access GILD’s Growth, Momentum, Stability, and Sentiment ratings.

Bottom Line

Despite the uncertain macroeconomic conditions, GILD has raised its guidance for fiscal 2022 based on solid demand for its therapies. The Sunlenca (Lenacapavir) drug holds immense promise for the company as it is expected to generate significant revenues, being the first and only approved Capsid Inhibitor-based HIV treatment option. With many analysts expecting an economic slowdown this year, investors could benefit from GILD’s impressive dividend yield.

GILD’s strong product pipeline, strategic acquisitions, collaborations, and drug approvals are expected to drive its growth in the long term. Given its robust financials, high profitability, solid dividend payouts, and discounted valuation, it could be wise to buy the stock now.

How Does Gilead Sciences, Inc. (GILD) Stack up Against Its Peers?

GILD has an overall POWR Rating of A, equating to a Strong Buy rating. Check out these other stocks within the Biotech industry with an A (Strong Buy) rating: United Therapeutics Corporation (UTHR - Get Rating), Vertex Pharmaceuticals Incorporated (VRTX - Get Rating), and Biogen Inc. (BIIB - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


GILD shares were trading at $82.70 per share on Tuesday morning, down $0.53 (-0.64%). Year-to-date, GILD has declined -3.67%, versus a 4.16% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
GILDGet RatingGet RatingGet Rating
UTHRGet RatingGet RatingGet Rating
VRTXGet RatingGet RatingGet Rating
BIIBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Gilead Sciences Inc. (GILD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GILD News